Three European nations are amending their policies in order to create better conditions for biosimilar uptake and the cost savings that biosimilars provide to health systems.
Three European nations are amending their policies in order to create better conditions for biosimilar uptake and the cost savings that biosimilars provide to health systems.
Finnish Medicines Agency Initiates Study on Biosimilars
The Finnish Medicines Agency (Fimea) has announced that it is beginning a study to investigate factors that promote or prevent the uptake of biosimilar therapies. The study, which will be jointly funded by the Finnish Social Insurance Institution Kela and the Ministry of Social Affairs and Health, will comprise interviews of physicians who treat rheumatic diseases, inflammatory bowel disease, psoriasis, and diabetes in both university hospitals and in central hospitals across Finland. Patients who receive biologic therapies will also take part in interviews.
Fimea expects to publish the study’s results in 2019, and says that the data will provide “…support of pharmaco-political decision-making and help in promoting the implementation of rational pharmacotherapy in Finland.”
Switzerland to Allow US-Licensed Comparator Biologics in Clinical Trials
The Swiss Agency for Therapeutic Products (Swissmedic) has updated its guidance concerning the use of comparator products used in clinical trials of biosimilars.
Previously, Swissmedic held that the only acceptable comparator products were those authorized in Switzerland or the European Union, though for supplementary studies (non-pivotal studies on pharmacodynamics, pharmacokinetics, and additional studies on efficacy and safety), comparator products from Japan were accepted. In its updated guidance, Swissmedic says that comparator products can now originate from the United States, and for supplementary studies, Canadian products will be allowed.
If the reference drug (the originator biologic approved in Switzerland) and the comparator products are not identical, their equivalence must be demonstrated.
Biosimilar developers will also be required to submit an Environmental Risk Assessment to Swissmedic.
France Seeks to Reach 80% Biosimilar Penetration by 2022
RAPS reports that France has committed to increasing biosimilar penetration to 80% by 2022 in its new health strategy for 2018 to 2022. According to the plan’s objective, when biosimilar products are available, 80% of patients should receive biosimilar options rather than reference biologics (a 10% increase on last year’s target numbers). The plan also encourages the non-medical switching of patients who are already receiving biologic therapy to treatment with available biosimilars.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.